Citations

Clear

6274 citation(s) found for "To, Andrew".

Peripheral Nerve Blockade with Combined Standard and Liposomal Bupivacaine in Major Lower‐Extremity Amputation
Dumitrascu, Catalina I. , Warner, Nafisseh S. , Stewart, Thomas M. , Amundson, Adam W. , Bruns, Danette, Hanson, Andrew C. , Schulte, Phillip J. , Brown, Michael , Niesen, Adam D. , Bruns, Danette L., Warner, Matthew A , Warner, Nafisseh , Smith, Mark M. , Brown, Michael J., Mantilla, Carlos B. , Warner, Matthew A.

Mayo Clinic

Pain Practice | October 15, 2020 | Volume: 21 | Issue: 3 | Pages: 299-307

10.1111/papr.12959 | PMID 33058387 Get It

AbstractBackground and ObjectivesOptimizing perioperative analgesia for patients undergoing major lower‐extremity amputation remains a considerable challenge. The utility of liposomal bupivacaine as a component of peripheral nerve blockade for lower‐extremity amputation is unknown.MethodsWe conducted an observational study comparing three different perioperative analgesic techniques for adults undergoing major lower‐extremity amputation under general anesthesia between 2012 and 2017 at an academic medical center: (1) no regional anesthesia, (2) peripheral nerve blockade with standard bupivacaine, and (3) peripheral nerve blockade with a mixture of standard and liposomal bupivacaine. The primary outcome of cumulative opioid oral morphine milligram equivalent utilization in the first 72 hours postoperatively was compared across groups utilizing multivariable linear regression.ResultsA total of 631 unique anesthetics were included for 578 unique patients, including 416 (66%) without regional anesthesia, 131 (21%) with peripheral nerve blockade with a mixture of standard and liposomal bupivacaine, and 84 (13%) with peripheral nerve blockade with standard bupivacaine alone. Cumulative morphine equivalents were lower in those receiving peripheral nerve blockade with combined standard and liposomal bupivacaine compared with those not receiving regional anesthesia (multiplicative increase 0.67; 95% CI 0.50 to 0.90; P = 0.007). There were no significant differences in opioid utilization between peripheral nerve blockade groups (P = 0.59).ConclusionsPeripheral nerve blockade is associated with reduced opioid requirements after lower‐extremity amputation compared with general anesthesia alone. However, the incorporation of liposomal bupivacaine is not significantly different to blockade employing only standard bupivacaine.
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial
Voso, Maria Teresa , Larson, Richard A. , Marcucci, Guido , Prior, Thomas W., Krauter, Jürgen, Heuser, Michael , Nomdedéu, Josep , Geyer, Susan M. , Wei, Andrew H. , Sierra, Jorge , Sanz, Miguel Á. , Brandwein, Joseph , Witte, Theo M. de, Niederwieser, Dietger , Appelbaum, Frederick R. , Medeiros, Bruno C. , Tallman, Martin S. , Schlenk, Richard F. , Ganser, Arnold , Cheng, Yuan, Chen, Yin-Miao, Pallaud, Céline , Du, Ling, Piciocchi, Alfonso , Ehninger, Gerhard , Byrd, John C. , Thiede, Christian , Döhner, Konstanze , Stone, Richard M. , Bloomfield, Clara D. , Byrd, John C. , Larson, Richard A , Wei, Andrew H , Jones, Dan M. , Lavorgna, Serena , Walker, Alison , Jansen, Joop H. , Amadori, Sergio , Cheng, Yuan, Döhner, Hartmut , Lo‐Coco, Francesco , Voso, Maria Teresa , Byrd, John C

Mayo Clinic

Blood Advances | October 13, 2020 | Volume: 4 | Issue: 19 | Pages: 4945-4954

10.1182/bloodadvances.2020002904 | PMID 33049054 Get It

Abstract The results from the RATIFY trial (ClinicalTrials.gov: NCT00651261; CALGB 10603) showed that midostaurin combined with standard chemotherapy significantly improved outcomes in patients with FMS-like tyrosine kinase 3 (FLT3)–mutated acute myeloid leukemia (AML), compared with placebo. In this post hoc subgroup analysis from the trial, we evaluated the impact of midostaurin in 163 patients with FLT3-tyrosine kinase domain (TKD) mutations. At a median follow-up of 60.7 months (95% CI, 55.0-70.8), the 5-year event-free survival (EFS) rate was significantly higher in patients treated with midostaurin than in those treated with placebo (45.2% vs 30.1%; P = .044). A trend toward improved disease-free survival was also observed with midostaurin (67.3% vs 53.4%; P = .089), whereas overall survival (OS) was similar in the 2 groups. Patients with AML and NPM1mut/FLT3-TKDmut or core binding factor (CBF)–rearranged/FLT3-TKDmut genotypes had significantly prolonged OS with or without censoring at hematopoietic cell transplantation (HCT), compared with NPM1WT/CBF-negative AMLs. The multivariable model for OS and EFS adjusted for allogeneic HCT in first complete remission as a time-dependent covariable, revealed NPM1 mutations and CBF rearrangements as significant favorable factors. These data show that NPM1 mutations or CBF rearrangements identify favorable prognostic groups in patients with FLT3-TKD AMLs, independent of other factors, also in the context of midostaurin treatment.
Diagnostic Imaging for Kidney Stones—Reply
Pais, Vernon M., Rule, Andrew D. , Lieske, John C.

Mayo Clinic

JAMA | October 13, 2020 | Volume: 324 | Issue: 14 | Pages: 1465

10.1001/jama.2020.14877 | PMID 33048149 Get It

Continuous lenalidomide and low‐dose dexamethasone in patients with transplant‐ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients
Belch, Andrew R. , White, Darrell , Cheung, Matthew C. , Chen, Christine , Shustik, Chaim, Song, Kevin , Tosikyan, Axel, Brown, Diane , Robinson, Suzanne, Srinivasan, Shankar , Belch, Andrew , Cheung, Matthew , Bahlis, Nizar Jacques , Dispenzieri, Angela , Anderson, Kenneth C. , Facon, Thierry T.F.

Mayo Clinic

Cancer Medicine | October 13, 2020 | Volume: 9 | Issue: 23 | Pages: 8923-8930

10.1002/cam4.3511 | PMID 33049118 Get It

AbstractThe phase 3 FIRST trial demonstrated significant improvement in progression‐free survival (PFS) and overall survival (OS) with an immune‐stimulatory agent, lenalidomide, in combination with low‐dose dexamethasone until disease progression (Rd continuous) vs melphalan +prednisone + thalidomide (MPT) in transplant‐ineligible patients with newly diagnosed multiple myeloma (NDMM). Rd continuous similarly extended PFS vs fixed‐duration Rd for 18 cycles (Rd18). Outcomes in the Canadian/US subgroup (104 patients per arm) are reported in this analysis. Rd continuous demonstrated a significant improvement in PFS vs MPT (median, 29.3 vs 20.2 months; HR, 0.69 [95% CI, 0.49‐0.97]; p = 0.03326) and an improvement vs Rd18 (median, 21.9 months). Median OS was 56.9 vs 46.8 months with Rd continuous vs MPT (p = 0.15346) and 59.5 months with Rd18. The overall response rate was higher with Rd continuous and Rd18 (78.8% and 79.8%) vs MPT (65.4%). In the 49.0%, 52.9%, and 29.8% of patients with at least very good partial response in the Rd continuous, Rd18, and MPT arms, respectively, the median PFS was 56.0, 30.9, and 40.2 months, respectively. The most common grade 3/4 treatment‐emergent adverse events were neutropenia (28.4%, 30.1%, and 52.0%), anemia (23.5%, 21.4%, and 23.5%), and infections (37.3%, 30.1%, and 24.5%) with Rd continuous, Rd18, and MPT, respectively. These results were consistent with those in the intent‐to‐treat population, confirming the benefit of Rd continuous vs MPT in the Canadian/US subgroup and supporting the role of Rd continuous as a standard of care for transplant‐ineligible patients with NDMM.
Surgical menopause: health implications and hormonal management
Kaunitz, Andrew M., Faubion, Stephanie, Faubion, Stephanie S.

Mayo Clinic

Menopause | October 13, 2020 | Volume: 28 | Issue: 1 | Pages: 1-3

10.1097/gme.0000000000001680 | PMID 33048864 Get It

Bipedicled submental musculofascial “hammock” flap for salvage laryngectomy closure reinforcement
Hayden, Richard E. , Chang, Brent A. , Mullin, David, Patel, Andrew K., Nagel, Thomas H. , Howard, Brittany E. , Hinni, Michael L., Donald, Carrlene B., Chang, Brent A , Lott, David G.

Mayo Clinic

Head & Neck | October 12, 2020 | Volume: 43 | Issue: 1 | Pages: 198-202

10.1002/hed.26473 | PMID 33043533 Get It

AbstractBackgroundThe aim of the study was to describe a novel technique for reinforcement of salvage laryngectomy closure using a bipedicled musculofascial submental flap.MethodsA retrospective cohort study design identified patients who underwent salvage laryngectomy reinforcement with a bipedicled submental hammock flap between January 2008 and December 2016 were compared to salvage laryngectomy patients treated with primary closure of the neopharynx during the same time period. Pharyngocutaneous fistula rates were compared between groups.ResultsPharyngocutaneous fistula rate in the submental hammock group (2/31, 6.5%) was significantly lower compared to the primary closure group (14/45, 31%, P < .05).ConclusionThe bipedicled musculofascial submental hammock flap is a viable method for reinforcement of salvage laryngectomy defects. It has a favorable pharyngocutaneous fistula rate compared to primary closure alone and has unique advantages over conventional methods of reinforcement.
Dynamic prediction of renal survival using artificial intelligence: an international study of deeply phenotyped cohorts of kidney transplant recipients
Loupy, Alexandre , Raynaud, Marc , Bailly, É. , Ladrière, Marc, Delahousse, Michel, Linhares, Kamilla, Castro, Maria Cristina Ribeiro de , Gervacio, Soler Pujol, Empana, Jean‐Philippe , Ulloa, Camilo , Böhmig, Georg A. , Huang, Edmund , Legendre, Christophe , Jouven, Xavier , Lefaucheur, Carmen , Loupy, Alexandre , Bailly, Élodie , Aubert, Olivier, Reese, Peter P. , Kamar, Nassim , Chin, Chen-Shan , Quintrec, Moglie Le , Jurić, Ivana , Bašić‐Jukić, Nikolina , Crespo, Marta , Junior, Helio Tedesco Silva , Akalin, Enver , Glotz, Denis , Stegall, Mark D. , Bentall, Andrew , Montgomery, Robert A. , Jordan, Stanley C. , Oberbauer, Rainer W. , Segev, Dorry L. , Friedewald, John J.

Mayo Clinic

No container title available | October 9, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-85478/v1 Get It

Abstract The authors have requested that this preprint be removed from Research Square.
The National Academies of Science, Engineering, and Medicine (NASEM) Report on Compounded Bioidentical Hormone Therapy
Pinkerton, JoAnn V. , Kaunitz, Andrew M., Liu, James H., Shifren, Jan L. , Stuenkel, Cynthia A. , Faubion, Stephanie S. , Manson, JoAnn E. , Santoro, Nanette F.

Mayo Clinic

Menopause | October 8, 2020 | Volume: 27 | Issue: 11 | Pages: 1199-1201

10.1097/gme.0000000000001672 | PMID 33110032 Get It